Log in to your Inderes Free account to see all free content on this page.
Pharma Equity Group
0.09 DKK
-7.06 %
Less than 1K followers
PEG
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
-7.06 %
-9.32 %
0.00 %
-20.85 %
-30.81 %
-38.15 %
-91.95 %
-81.78 %
-99.64 %
Pharma Equity Group develops medicines for the treatment of serious and life-threatening inflammatory diseases for which there is currently no adequate treatment. The Company uses repositioning of existing medicines and takes drug candidates to a clinical Phase III stage, after which they are handed over to a strategic partner who will complete the development of the products and bring them to market, either independently or in collaboration with the Company.
Read moreMarket cap
114.65M DKK
Turnover
7.7K DKK
Revenue
EBIT %
P/E
Dividend yield-%
Coverage
Latest research
Latest analysis report
Released: 10.09.2025
Revenue and EBIT-%
Revenue
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
18.3.
2026
Annual report '25
16.4.
2026
General meeting '26
14.8.
2026
Interim report Q2'26
All
Research
Webcasts
Press releases
3rd party
ShowingAll content types
Pharma Equity Group – Strategic update and adjustment of expectations
Pharma Equity Group executes on the Company's new strategy: Enters into Letter of Intent to acquire the MedTech company Otiom A/S
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
